Drug Database
PE

peginterferon alfa-2b (Pegstat)

✓ Approved

Nanogen Biopharmaceutical · IFNAR2 · 重组蛋白

什么是 peginterferon alfa-2b?

peginterferon alfa-2b 是一种重组蛋白,由Nanogen Biopharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Pegstat
公司Nanogen Biopharmaceutical
药物类别重组蛋白
分子靶点IFNAR2
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

peginterferon alfa-2b 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

peginterferon alfa-2b 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Hepatobiliary disordersHepatic cirrhosis✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved

相关研究文献

PubMedResearch and practice in thrombosis and haemostasis2026-11-20

Efanesoctocog alfa in mild hemophilia A.

Miesbach Wolfgang W, Fleck Erika E, Gatzke Florian F, Hoffmann Pascal P et al.

Pivotal trials of efanesoctocog alfa enrolled only people with severe hemophilia A; its use in nonsevere disease is limited to mixed-severity cohorts and a single case report of a woman. Mild disease differs: endogenous factor (F)VIII persists, and inhibitor risk is lifelong. To describe real-world use of efanesoctocog alfa in mild hemophilia A. We conducted a single-center, retrospective review of consecutive individuals with mild hemophilia A, including symptomatic carriers, treated between October 2025 and June 2026. FVIII activity was measured by a one-stage assay (Actin FSL). Thirteen individuals (12 men, 1 symptomatic carrier; median age, 56 years; range, 24-86) with baseline FVIII levels of 8% to 57% underwent 17 treatment episodes: 10 perioperative or procedural, 4 on-demand, and 3 prophylactic. Doses of 12 to 37 IU/kg achieved adequate hemostasis in all procedures and bleeds; 3 of 14 (2 varicose vein operations and 1 knee bleed) received a second dose. In 4 episodes, activity was 50% to 72% on days 3 to 4. Prophylaxis was administered at 26 to 40 IU/kg (median, 30) weekly or every 5 days, with trough levels of 33% to 70% (median, 61%). All injections were given on an outpatient basis. FVIII was measured in 7 of 17 episodes. No inhibitors, thrombosis, or hypersensitivity occurred. In this first series dedicated to mild hemophilia A, efanesoctocog alfa, individualized to residual FVIII, provided adequate hemostasis at doses well below the label. A single FVIII measurement on day 3 or 4, using a product-validated assay, may replace routine monitoring. Further observations require prospective study with long-term inhibitor surveillance.

PMID 43061157
阅读全文 →
PubMedFoodborne pathogens and disease2026-11-20

Genetic and Phenotypic Characterization of Listeria monocytogenes Isolates from Cattle Slaughterhouses in Korea.

Hong Serim S, Moon Jin-San JS, Kim Ha-Young HY

Listeria monocytogenes is a foodborne pathogen notable for its ability to persist in diverse environmental conditions and its genetic diversity across food and processing environments. This study aimed to characterize the genetic and phenotypic profiles of L. monocytogenes isolates obtained from cattle carcasses and slaughterhouse environments in Korea. Between 2020 and 2022, a total of 36 L. monocytogenes isolates were obtained from 8 of the 26 cattle slaughterhouses. Serotype 1/2a was the most prevalent (44.4%), followed by 1/2b (38.9%), 1/2c (8.3%), and 4b (8.3%). All isolates carried hlyA, mpl, plcB, inlA, inlB, inlC, and inlJ, while actA and plcA were detected in 97.2% and prfA in 94.4% of isolates. In contrast, llsX (Listeria pathogenicity island [LIPI]-3) and stress survival islet-1 were found in 41.7% and 50.0% of isolates, respectively, while ptsA (LIPI-4) was not detected. Pulsed-field gel electrophoresis analysis identified 16 different pulsotypes. Multilocus sequence typing identified 10 sequence types (STs), with ST324, ST8, ST224, and ST14 being the predominant types. These were grouped into eight clonal complexes (CCs) and classified into two evolutionary lineages: lineage I (CC5, CC6, CC224, and CC288) and lineage II (CC8, CC9, CC14, and CC121). Antimicrobial resistance analysis showed that all serotype 1/2b isolates were resistant to oxacillin, all serotype 1/2c (CC9) isolates were resistant only to tetracycline, while all serotype 4b (CC6) isolates were resistant to both daptomycin and oxacillin. These findings provide insights into the genetic diversity, virulence profiles, and antimicrobial resistance of L. monocytogenes in cattle slaughterhouses and provide baseline information for improving hygiene practices and food safety management.

PMID 43062014
阅读全文 →
PubMedCureus2026-11-20

Autoimmune Overlap of Systemic Lupus Erythematosus and Myasthenia Gravis: A Case Report and Emerging Therapeutic Strategies.

Chadalavada Bhavya B, Baddam Ritesh Reddy RR, Sinitsa Isabelle I, Dhamsania Rohan K RK

Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are autoimmune disorders that predominantly affect women and may coexist, though their overlap remains rare. Shared mechanisms, including loss of immune tolerance, B-cell hyperactivity, and dysregulated cytokine signaling, are thought to underlie this association. We report the case of a 56-year-old woman diagnosed with seronegative MG after presenting with progressive proximal weakness, ocular involvement, and electrophysiologic evidence of neuromuscular junction dysfunction. She was stabilized on IVIG, pyridostigmine, and azathioprine. Four years later, she developed a malar rash, polyarthralgia, and bilateral upper-extremity numbness; serologic evaluation confirmed SLE and revealed newly detectable acetylcholine receptor binding antibodies, representing her first positive MG serologic marker. Hydroxychloroquine (HCQ) and methotrexate were added to her regimen. Efgartigimod alfa, a neonatal Fc receptor (FcRn) antagonist, was subsequently initiated for persistent MG and produced marked improvement in MG Activities of Daily Living (MG-ADL) scores. Her SLE-related joint symptoms also improved, although SLE-directed therapy had been adjusted during the same period. However, cyclic dosing resulted in consistent symptomatic wear-off in the days preceding each treatment cycle. Transition to nipocalimab, a fixed-schedule anti-FcRn monoclonal antibody providing continuous IgG suppression, is under multidisciplinary consideration. This case highlights the diagnostic and therapeutic complexity of SLE-MG overlap and suggests that FcRn inhibition may offer a mechanistically rational approach to IgG-mediated disease in both conditions, a possibility that warrants further study.

PMID 43061234
阅读全文 →
PubMedmedRxiv : the preprint server for health sciences2026-11-20

Path to Prevention Platform Trial in Early-Stage Neuronal Alpha-Synuclein Disease: Study Design.

Schneider Ruth B RB, Coffey Christopher S CS, Kopil Catherine M CM, Kuhl Maggie M MM et al.

The development of biologically targeted therapeutics (BTTs) that slow Parkinson's disease progression has been hampered by a reliance on testing interventions in clinically defined populations with already advanced pathobiology. Publications on the biological definition and classification of neuronal ⍰-synuclein disease (NSD), and the development of the NSD integrated staging system (NSD-ISS), have generated a framework for identifying individuals with NSD prior to the emergence of a clinically defined syndrome. Path to Prevention (P2P) is a phase 2A, randomized, double-blind, placebo-controlled platform trial designed to assess the safety and efficacy of interventions in an early-stage NSD population. The trial is embedded within the observational Parkinson's Precision Medicine Initiative (PPMI), a structure that enables recruitment of participants from the PPMI cohort, leverages existing operational infrastructure, and utilizes data from non-P2P enrolled PPMI participants in the Bayesian statistical modeling. P2P will enroll participants at least 60 years of age with NSD Stage 2B (abnormal ⍰-synuclein, dopaminergic dysfunction, and prodromal signs or symptoms without functional impairment) without a clinically defined diagnosis of PD or a related disorder. As a platform trial, P2P will enable the testing of multiple interventions under a Master Protocol at approximately 35 sites across North America and Europe. Interventions are selected from industry-submitted applications based on biological relevance of the targets, and on the adequacy of the safety data appropriate to the target population. Each treatment regimen will have 125 participants on active treatment and at least 125 shared placebo control participants. Participants will remain on treatment for a maximum of 144 weeks or until 96 weeks since the randomization of the last participant. P2P has two primary endpoints, 1) rate of change in mean putamen specific binding ratio from baseline through follow-up and, 2) rate of change in the MDS-UPDRS Part III motor examination from baseline through follow-up or initiation of dopaminergic treatment. A range of secondary and exploratory biomarker-focused endpoints will be assessed. The protocol was developed with input from multiple stakeholders, including people with early-stage NSD, biopharmaceutical industry leaders, and regulatory authorities. P2P is the first trial to test biologically targeted assets in biologically defined prodromal participants utilizing an efficient platform design, which will provide the field with tools to expand therapeutic development, and enable intervention at earlier stages of neurodegeneration. P2P is scheduled to begin enrollment in December 2026 and is committed to data sharing and broad dissemination of learnings from the study.

PMID 43060735
阅读全文 →
PubMedVirus research2026-11-19

Early Hematologic and Liver Biochemical Dynamics During Pegylated Interferon-α-2b Therapy and Their Associations With Subsequent HBsAg Clearance in Chronic HBV Infection: A Dual-Center Landmark Cohort Study.

Jiang Runci R, Cheng Shuqin S, Zhao Meiqi M, Wang Fengmei F

The relevance of routine laboratory changes during pegylated interferon therapy remains uncertain. We examined associations between early laboratory changes and subsequent hepatitis B surface antigen (HBsAg) clearance in chronic hepatitis B virus infection. This retrospective two-center cohort included adults receiving pegylated interferon-α-2b (PEG-IFNα-2b). Eight hematologic and liver biochemical markers were measured at baseline and weeks 12 and 24. A week-24 landmark separated early laboratory changes from subsequent HBsAg clearance through week 72. Linear mixed-effects models evaluated longitudinal patterns, and discrete-time survival models assessed associations after adjustment for clinical covariates and week-24 HBsAg. Benjamini-Hochberg correction addressed multiple testing, and incremental prediction was evaluated using bootstrap internal validation. Among 269 patients, 47 (17.5%) achieved HBsAg clearance after week 24 and by week 72. Greater lymphocyte recovery during weeks 12-24 was associated with subsequent clearance (adjusted HR per 1-SD increase, 1.93; 95% CI, 1.43-2.62; FDR-adjusted P < 0.001). This association persisted after further adjustment for HBsAg kinetics and in ridge-penalized analyses. In the complete-case analysis (n = 267), adding lymphocyte change to the model increased the optimism-corrected week-72 AUC from 0.757 to 0.805; the corrected calibration slope was 0.548. Latent trajectory classes were not significantly associated with HBsAg clearance. Greater lymphocyte recovery during weeks 12-24 remained associated with subsequent HBsAg clearance after adjustment for HBsAg kinetics. This routinely available measure warrants prospective validation as an on-treatment response marker.

PMID 43057657
阅读全文 →
PubMedFood chemistry2026-11-19

Pressure-dependent structural changes and in vitro digestive behavior of soybean meal protein induced by explosion puffing.

Lee Seonmin S, Oh Seon-Min SM, Jung Samooel S, Choi Yun-Sang YS

Explosion puffing (EP) was investigated as a processing method to improve the in vitro protein digestibility of soybean meal powder. Soybean meal powder was treated at 2, 3, and 4 bar (SP-2B, SP-3B, and SP-4B) using a gun-puffing system. Fourier transform infrared and circular dichroism spectroscopy analyses showed that SP-3B and SP-4B exhibited reduced α-helix and increased β-sheet content (P < 0.05). Increasing pressure also increased reactive sulfhydryl content and surface hydrophobicity (P < 0.05), accompanied by tryptophan fluorescence quenching and red shift (P < 0.05). Microscopy analyses revealed progressive disruption of the cell wall network, while sodium dodecyl sulfate-polyacrylamide gel electrophoresis results showed protein aggregation. Despite aggregation, all EP-treated samples released significantly more α-amino groups during intestinal digestion than untreated soybean meal (P < 0.05). SP-2B generated the highest proportion of low-molecular-weight (<3 kDa) proteins (P < 0.05). These results demonstrate that EP can effectively enhance soybean meal protein digestibility, highlighting its potential as a value-added plant-based protein ingredient.

PMID 43056826
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多peginterferon alfa-2b